 Proto-Oncogene Proteins c-ret
"Proto-Oncogene Proteins c-ret" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Receptor protein-tyrosine kinases involved in the signaling of GLIAL CELL-LINE DERIVED NEUROTROPHIC FACTOR ligands. They contain an extracellular cadherin domain and form a receptor complexes with GDNF RECEPTORS. Mutations in ret protein are responsible for HIRSCHSPRUNG DISEASE and MULTIPLE ENDOCRINE NEOPLASIA TYPE 2.
| Descriptor ID |
D051096
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.087 D12.776.395.550.200.188.500 D12.776.543.131.500 D12.776.543.750.630.217 D12.776.624.664.700.194
|
| Concept/Terms |
Proto-Oncogene Proteins c-ret- Proto-Oncogene Proteins c-ret
- Proto Oncogene Proteins c ret
- c-ret, Proto-Oncogene Proteins
- Receptor Tyrosine Kinase RET
- ret Proto-Oncogene Proteins
- Proto-Oncogene Proteins, ret
- ret Proto Oncogene Proteins
- Proto-Oncogene Protein c-ret
- Proto Oncogene Protein c ret
- c-ret, Proto-Oncogene Protein
- c-ret Protein
- Proto-Oncogene Protein Ret
- Proto Oncogene Protein Ret
- Ret, Proto-Oncogene Protein
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-ret".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-ret".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-ret" by people in this website by year, and whether "Proto-Oncogene Proteins c-ret" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2012 | 1 | 0 | 1 | | 2013 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2017 | 3 | 2 | 5 | | 2018 | 1 | 1 | 2 | | 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-ret" by people in Profiles.
-
Rich TA, Reckamp KL, Chae YK, Doebele RC, Iams WT, Oh M, Raymond VM, Lanman RB, Riess JW, Stinchcombe TE, Subbiah V, Trevarthen DR, Fairclough S, Yen J, Gautschi O. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. Clin Cancer Res. 2019 10 01; 25(19):5832-5842.
-
Ng TL, Liu Y, Dimou A, Patil T, Aisner DL, Dong Z, Jiang T, Su C, Wu C, Ren S, Zhou C, Camidge DR. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. Cancer. 2019 04 01; 125(7):1038-1049.
-
Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. Cancer Discov. 2019 03; 9(3):384-395.
-
Reeser JW, Martin D, Miya J, Kautto EA, Lyon E, Zhu E, Wing MR, Smith A, Reeder M, Samorodnitsky E, Parks H, Naik KR, Gozgit J, Nowacki N, Davies KD, Varella-Garcia M, Yu L, Freud AG, Coleman J, Aisner DL, Roychowdhury S. Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors. J Mol Diagn. 2017 09; 19(5):682-696.
-
Nelson-Taylor SK, Le AT, Yoo M, Schubert L, Mishall KM, Doak A, Varella-Garcia M, Tan AC, Doebele RC. Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling. . 2017 08; 16(8):1623-1633.
-
Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017 May 01; 35(13):1403-1410.
-
Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, de Cubas AA, Wenz B, Korpershoek E, Amelio AL, Makowski L, Rathmell WK, Gimenez-Roqueplo AP, Giordano TJ, Asa SL, Tischler AS, Pacak K, Nathanson KL, Wilkerson MD. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell. 2017 02 13; 31(2):181-193.
-
Turner J, Couts K, Sheren J, Saichaemchan S, Ariyawutyakorn W, Avolio I, Cabral E, Glogowska M, Amato C, Robinson S, Hintzsche J, Applegate A, Seelenfreund E, Gonzalez R, Wells K, Bagby S, Tentler J, Tan AC, Wisell J, Varella-Garcia M, Robinson W. Kinase gene fusions in defined subsets of melanoma. Pigment Cell Melanoma Res. 2017 01; 30(1):53-62.
-
Azar FK, Lee SL, Rosen JE. Medullary thyroid cancer: an update for surgeons. Am Surg. 2015 Jan; 81(1):1-8.
-
Fishbein L, Merrill S, Fraker DL, Cohen DL, Nathanson KL. Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol. 2013 May; 20(5):1444-50.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|